Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oncolytic Virus + Chemotherapy + PD-1 Inhibitor in Locally Advanced ESCC
NCT07061704Phase 2Recruiting
- Sponsor
- Sichuan University
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 2 trial of IDOV-Immune in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sichuan University. Started Aug 2025; status: recruiting.
02
Drugs
IDOV-Immune
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07061704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07061704.